JP2002087963A - 直接打錠により製造されたエピナスチン含有錠剤 - Google Patents

直接打錠により製造されたエピナスチン含有錠剤

Info

Publication number
JP2002087963A
JP2002087963A JP2000315849A JP2000315849A JP2002087963A JP 2002087963 A JP2002087963 A JP 2002087963A JP 2000315849 A JP2000315849 A JP 2000315849A JP 2000315849 A JP2000315849 A JP 2000315849A JP 2002087963 A JP2002087963 A JP 2002087963A
Authority
JP
Japan
Prior art keywords
epinastine
tablet
tablets
hydrochloride
direct compression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000315849A
Other languages
English (en)
Japanese (ja)
Inventor
Toshimitsu Oki
俊光 大木
Mannen Yokoyama
万年 横山
Wakuko Yamaguchi
和久子 山口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Boehringer Ingelheim Co Ltd
Original Assignee
Nippon Boehringer Ingelheim Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Boehringer Ingelheim Co Ltd filed Critical Nippon Boehringer Ingelheim Co Ltd
Priority to JP2000315849A priority Critical patent/JP2002087963A/ja
Priority to PCT/EP2001/010139 priority patent/WO2002020018A1/en
Priority to MXPA03002013A priority patent/MXPA03002013A/es
Priority to AU2001291820A priority patent/AU2001291820A1/en
Priority to BR0113731-0A priority patent/BR0113731A/pt
Publication of JP2002087963A publication Critical patent/JP2002087963A/ja
Priority to EC2003004501A priority patent/ECSP034501A/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000315849A 2000-09-08 2000-09-08 直接打錠により製造されたエピナスチン含有錠剤 Pending JP2002087963A (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000315849A JP2002087963A (ja) 2000-09-08 2000-09-08 直接打錠により製造されたエピナスチン含有錠剤
PCT/EP2001/010139 WO2002020018A1 (en) 2000-09-08 2001-09-04 Tablets containing epinastine manufactured by direct compression
MXPA03002013A MXPA03002013A (es) 2000-09-08 2001-09-04 Comprimidos que contienen epinatina fabricados por compresion directa.
AU2001291820A AU2001291820A1 (en) 2000-09-08 2001-09-04 Tablets containing epinastine manufactured by direct compression
BR0113731-0A BR0113731A (pt) 2000-09-08 2001-09-04 Comprimidos contendo epinastina produzidos por compressão direta
EC2003004501A ECSP034501A (es) 2000-09-08 2003-03-05 Comprimidos que contienen epinastina fabricados por compresion directa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000315849A JP2002087963A (ja) 2000-09-08 2000-09-08 直接打錠により製造されたエピナスチン含有錠剤

Publications (1)

Publication Number Publication Date
JP2002087963A true JP2002087963A (ja) 2002-03-27

Family

ID=18794888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000315849A Pending JP2002087963A (ja) 2000-09-08 2000-09-08 直接打錠により製造されたエピナスチン含有錠剤

Country Status (6)

Country Link
JP (1) JP2002087963A (es)
AU (1) AU2001291820A1 (es)
BR (1) BR0113731A (es)
EC (1) ECSP034501A (es)
MX (1) MXPA03002013A (es)
WO (1) WO2002020018A1 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008201713A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd フィルムコーティング用組成物
JP2009114069A (ja) * 2007-11-01 2009-05-28 Sawai Pharmaceutical Co Ltd 口腔内崩壊錠
JP2012211101A (ja) * 2011-03-31 2012-11-01 Ssp Co Ltd フィルムコーティング用組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2494065A1 (en) * 2002-08-02 2004-02-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
EP1041990B1 (en) * 1997-12-23 2006-06-28 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
EP1000623A1 (en) * 1998-09-29 2000-05-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Use of epinastine as antitussivum
JP4016128B2 (ja) * 1999-09-09 2007-12-05 東和薬品株式会社 耐光性塩酸エピナスチンフィルムコート錠

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008201713A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd フィルムコーティング用組成物
JP2009114069A (ja) * 2007-11-01 2009-05-28 Sawai Pharmaceutical Co Ltd 口腔内崩壊錠
JP2012211101A (ja) * 2011-03-31 2012-11-01 Ssp Co Ltd フィルムコーティング用組成物

Also Published As

Publication number Publication date
BR0113731A (pt) 2003-07-29
WO2002020018A8 (en) 2002-09-19
MXPA03002013A (es) 2003-07-24
AU2001291820A1 (en) 2002-03-22
ECSP034501A (es) 2003-04-25
WO2002020018A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
RU2401125C2 (ru) Способ стабилизации лекарственного средства против деменции
EP2760821B1 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
WO2009101940A1 (ja) 溶出性の改善された錠剤
WO2001034147A1 (fr) Preparation solide orale
WO2010113840A1 (ja) ソリフェナシン非晶質体を含有した固形医薬組成物
WO2009066315A2 (en) Sustained release compositions of trimetazidine and process for preparation thereof
WO2016136849A1 (ja) 固形製剤
EP1335707A2 (en) Novel formulations of carvedilol
EP3162363B1 (en) Composite preparation comprising active ingredient-containing film coating layer
PL211062B1 (pl) Kompozycja farmaceutyczna do podawania doustnegozawierająca flibanserynę oraz zastosowanie kompozycji
EP1976522B1 (en) Pharmaceutical composition containing montelukast
US20040019096A1 (en) Novel formulations of carvedilol
EP0393572A2 (en) Controlled release tablets containing flavoxate
EP3648745B1 (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
RU2444359C1 (ru) Фармацевтическая композиция с 2-этил-6-метил-3-гидроксипиридина сукцината для перорального применения и способ ее получения
KR20010061927A (ko) 라소폭시펜의 투여요법
JP5318400B2 (ja) レボフロキサシン含有錠剤
WO2017142438A1 (ru) Таблетки клозапина с замедленным высвобождением и способ их получения
KR102481517B1 (ko) 약제학적 제제
US20030153617A1 (en) Simvastatin dosage forms
US20060193915A1 (en) Compression coated tablets
JP2002087963A (ja) 直接打錠により製造されたエピナスチン含有錠剤
EP2559431A1 (en) Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
EP2101742B1 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
KR20160014619A (ko) 공-결정체 형태로 아고멜라틴을 포함하는 아고멜라틴 제형

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20041025